We’re Solving Obesity. Now Who Pays for It?

This week on On The Pen, the GLP-1 story is moving in two very different directions.

The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatide shortages, FDA updated its consumer guidance around compounded GLP-1 medications and multi-dose vials, and employers continue questioning whether they can afford obesity-drug coverage.

At the same time, the medical case for these medications keeps getting stronger.

We break down Mounjaro’s new cardiovascular indication and what preventing heart attacks and strokes could mean for the true long-term cost of GLP-1 treatment. We also look at 600,000 Medicare beneficiaries already enrolling in the $50 GLP-1 Bridge program, California’s effort to tackle affordability, the rapidly expanding oral GLP-1 market, and new real-world data on patients staying at lower doses of semaglutide and tirzepatide.

The science is expanding. Access is contracting.

And that may be the biggest challenge facing the next phase of the GLP-1 revolution.

In this episode:
• What the Fifth Circuit compounding decisions actually mean
• FDA’s updated language around compounded GLP-1 vials
• The 28-day multi-dose vial controversy
• Mounjaro’s new cardiovascular indication
• Why GLP-1s may reduce long-term healthcare costs
• Employers dropping obesity-drug coverage
• 600,000 people joining the Medicare GLP-1 Bridge
• California’s push for lower GLP-1 prices
• The oral GLP-1 race
• New data on lower-dose semaglutide and tirzepatide

Follow everything On The Pen:

This episode is sponsored by VoaFit.
https://www.voafit.com/otp

This content is for informational and educational purposes only and is not medical advice. Always discuss medication and treatment decisions with a qualified healthcare professional.